PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Hannah Buckley(University of Leeds), Naveen Vasudev(University of Leeds), Rosamonde E. Banks(Cancer Research UK), Fiona Collinson(St James's University Hospital), Galina Velikova(University of Leeds), Heather Poad(University of Leeds), Gemma Ainsworth(University of Leeds), Kate Fife(Addenbrooke's Hospital), Sarah Brown(University of Leeds), James Larkin(Trinity College Dublin), Geraldine Murden(University of Leeds), Paul Nathan(Mount Vernon Hospital), Eszter Katona(University of Leeds), Tom Waddell(The Christie NHS Foundation Trust), Helen Howard(University of Leeds), Thomas Powles(National Health Service), Louise Flanagan(University of Leeds)
Cited by 17
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k